STOCKHOLM, SWEDEN – 23 May 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company OssDsign has experienced a substantial step forward in the process towards reimbursement of OSSDSIGN Cranial PSI in France. Hauté Autorité de Santé (HAS), the French health technology assessment institute, has given an initial positive opinion regarding use of OssDsigns unique product for cranioplasty to be covered by the French national reimbursement system. France is the only remaining European key market where OSSDSIGN Cranial PSI to date lacks reimbursement.
Following the notice from HAS, OssDsign’s application can proceed to the next stage of the application process where a specific reimbursement level for OSSDSIGN Cranial PSI can be determined. As a result of the positive notice from HAS, OssDsign will now intensify its preparations for launching in France during the second half of 2019. France is the only key market in Europe where OssDsign, due to lack of reimbursement, has not yet launched OSSDSIGN Cranial PSI. OssDsign has already established sales organizations and has access to reimbursement systems in the other key European markets.
For more information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com
Fredrik Järrsten, CFO, Karolinska Development AB
Phone: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has established a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information: www.karolinskadevelopment.com.
This information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Viktor Drvota, at 14:00 CET on 23 May 2019.
Attachment
